Potential Near-Term Catalysts
• CYP-001 – Phase 2 trial in respiratory distress
• CYP-001 – Phase 2 trial in aGvHD
• CYP-004 – Phase 3 trial in knee osteoarthritis
• CYP-002 – Restarting trials in critical limb ischemia
• TBD (MSC-seeded silicon dressing) – Phase 1/2 in diabetic foot ulcers
Valuation $2.95 on Risk-Adjusted NPV
We value Cynata Therapeutics at A$408m or A$2.95 per share on an undiluted basis, using a risk-adjusted net present
value (rNPV) method to discount future cash flows through to 2034, consistent with the expiry of current patent
families.
Sensitivities and Risks
Cynata Therapeutics is subject to all the risks typically associated with biotech company drug development,
including the possibility of unfavourable outcomes in clinical trials, regulatory decisions, success of competitors,
financing, and commercial decisions by partners or potential partners, including timing.
https://files.cynata.com/662/MST-Access---CYP-Initiation-Report---11Jun21-%28002%29.pdf
Ann: Quarterly Activity Report & Appendix 4C, page-32
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.010(4.26%) |
Mkt cap ! $42.21M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 22.5¢ | $12.22K | 54.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 29947 | 2 |
View Market Depth
| Last trade - 11.02am 08/05/2024 (20 minute delay) ? |
| CYP (ASX) Chart |